The European Commission (EC) has at last granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing ...

Galapagos (Euronext: GLPG) said on Tuesday that its chief financial officer and chief operating officer Thad Huston will ...

German biotech HepaRegeniX has raised 21.5 million euros ($23 million) in new funding to support the clinical development of its lead candidate, HRX-215, a first-in-class treatment aimed at enhancing ...

Danish pharma major Novo Nordisk says that it has become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside its authorized supply chain in the USA.

Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results.

Cambridge, USA-based biotech Oak Hill Bio, which is focused on acquiring and developing life-changing rare disease therapeutics, has entered into an exclusive license agreement with Roche (ROG: SIX) ...

Privately-held US biotech Attovia Therapeutics, which is developing treatments for immune-mediated diseases with high unmet patient need, today announced the close of a $90 million Series C financing.

Austrian drug delivery specialist Cyprumed GmbH and US pharma giant Merck & Co (NYSE: MRK), known as MSD outside of the USA and Canada, have signed a non-exclusive license and option agreement to ...

New research from consultancy Vital Transformation has shown the effects of US policy the Inflation Reduction Act’s (IRA) drug pricing provisions on biopharmaceutical investment, research and ...

San Francisco, USA-based inflammatory disease biotech Third Harmonic Bio (Nasdaq: THRD) saw its shares rocket almost 40% to $5.09 as the company revealed an orderly exit plan.

US pharma major Bristol Myers Squibb (NYSE: BMY) yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos ...

French pharma major Sanofi (Euronext: SAN) has shared new progress from its mid- to late-stage respiratory pipeline. The Paris-based company has presented new Phase II data on amlitelimab, showing its ...